Founded in 2015, Triastek, Inc. is the global leader in the 3D printing of pharmaceuticals and is pioneering the implementation of digital pharmaceutical solutions. Triastek’s novel and proprietary 3D printing technology platform, encompasses dosage form design, digital pharmaceutical product development, and intelligent manufacturing.

Profile Description

Triastek has the largest product pipeline based on 3D printing technology in the world, with the company’s 1st and 2nd products (T19 and T20) having received IND clearance from the U.S. Food and Drug Administration (FDA). Triastek’s leadership is also demonstrated by acceptance into the U.S. FDA’s Emerging Technology Program (ETP) and participation in the discussion of 3D printing pharmaceutical standards led by United States Pharmacopoeia (USP). The company also holds the highest number of patent applications related to 3D printing of pharmaceuticals, providing the most comprehensive patent coverage of any 3D printing pharmaceutical company in the world.

Having completed 6 rounds of financing, Triastek is well-positioned to advance its product pipeline and positively impact patient health. Investors to date include: Tasly Holding Group, Morningside Venture Capital, Volcanics Venture, Dalton Venture, Yunqi Partners, Matrix Partners China, CPE, Shanghai Sci-Tech Innovation Center Capital, and Triwise Capital.

Leave a Comment

Time limit is exhausted. Please reload the CAPTCHA.

Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec_
  • wp-settings-
  • wp-settings-time-

Decline all Services
Accept all Services